0001818331 2021-07-22 2021-07-22 0001818331 dei:FormerAddressMember 2021-07-22 2021-07-22 0001818331 smfr:ClassCommonStockParValue0.0001PerShareMember 2021-07-22 2021-07-22 0001818331 smfr:WarrantsToPurchaseOneShareOfClassACommonStockEachAtAnExercisePriceOf1150PerShareMember 2021-07-22 2021-07-22 0001818331 true 8-K/A 2021-07-22 Sema4 Holdings Corp. DE 001-39482 85-1966622 333 Ludlow Street, North Tower, 8th Floor 06902 Stamford, CT 800 298-6470 CM Life Sciences, Inc. 667 Madison Avenue New York NY false false false false Class A common stock, par value $0.0001 per share SMFR NASDAQ Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share SMFRW NASDAQ true false This Amendment No. 1 on Form 8-K/A to the Original 8-K (this “Amendment” and the Original 8-K, as amended by this Amendment, this “Report”) is being filed to (a) provide updated financial statements including (i) the unaudited financial statements of Sema4 for the three and six months ended June 30, 2021, and (ii) the pro forma financial statements for the combined entities as of and for the three and six months ended June 30, 2021 and for the year ended December 31, 2020, and (b) amend the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” which was part of the Form 10 information disclosed under and incorporated by reference to Item 2.01 to the Original 8-K to reflect such unaudited financial statements.